Physician profile
Robert M Dohar
NPI 1659464543
$743.03
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $494 · 2020: $64.85 · 2021: $125 · 2023: $58.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $58.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $58.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $124.94 | 2021 | |
| Janssen Pharmaceuticals, INC | $111.31 | 2019 | |
| Abbvie INC. | $109.32 | 2019 | |
| Amarin Pharma, INC. | $62.25 | 2019-2020 | |
| Vapotherm INC | $58.98 | 2023 | Vapotherm |
| Lilly USA, LLC | $39.82 | 2019 | |
| Glaxosmithkline, LLC. | $31.17 | 2019 | |
| Novo Nordisk INC | $28.66 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $26.03 | 2019 | |
| Sunovion Pharmaceuticals INC. | $25.75 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.72 | 2019 | |
| Melinta Therapeutics, LLC | $18.08 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.81 | 2019 | |
| Mannkind Corporation | $15.29 | 2019 | |
| Allergan, INC. | $13.82 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $13.72 | 2019 | |
| Pfizer INC. | $11.44 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $10.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Dohar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.